News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No news articles were published in the past hour.
  • Headline flow paused, leaving few near-term catalysts for markets.
  • Trading likely to remain muted without fresh economic or geopolitical data.
  • Volatility expected to stay subdued until new releases or events emerge.
  • Investors will await scheduled economic data and corporate reports for direction.
  • Overall market risk sentiment unchanged absent fresh information.

Latest Articles

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Quantum BioPharma Ltd. announced the consolidation of its direct action lawsuit with a class action alleging stock price manipulation against Canadian banks CIBC and RBC. The U.S. District Court in New York appointed Grant & Eisenhofer as lead counsel for the class action. The lawsuits claim the defendants engaged in 'spoofing' to manipulate Quantu…

Amneal to Report Third Quarter 2026 Results on November 3, 2026

Amneal to Report Third Quarter 2026 Results on November 3, 2026

Amneal Pharmaceuticals announced it will release its third quarter 2026 financial results before market open on November 3, 2026. The company will host a live audio webcast for investors. Amneal is a diversified biopharmaceutical firm with a portfolio including generics, specialty, and biosimilars, servicing largely the U.S. market.

ROC Launches SaaS Product, Establishes Foundation for New Recurring Revenue Opportunities for its Vision AI Portfolio

ROC Launches SaaS Product, Establishes Foundation for New Recurring Revenue Opportunities for its Vision AI Portfolio

Rank One Computing Corporation (ROC), a U.S. Vision AI leader, launched its first SaaS product, the Age Estimation API, enabling developers direct and real-time access to its facial age estimation technology. This strategic move initiates ROC's plan to broaden its revenue base by offering additional SaaS and API solutions in facial analytics and bi…

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors

Aardvark Therapeutics, a Nasdaq-listed clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for metabolic diseases, has appointed David Zhang, Ph.D., MBA, as an independent director to its Board. Dr. Zhang brings over 25 years of experience in clinical strategy, biostatistics, and regulatory submissions from leading…

Core Scientific: AMD Approval Could Be the Spark — Buy the Dip While Financing and Colocation Momentum Line Up

Core Scientific: AMD Approval Could Be the Spark — Buy the Dip While Financing and Colocation Momentum Line Up

Core Scientific ($15.93) is trading near the low end of its 52-week range after a corrective stretch. Colocation revenue surged to $65M in 2025 from $24M in 2024, management secured near-term financing, and reports of AMD approval for hosting/AI workloads — if confirmed - materially de-risks capacity monetization. With a market cap near $5.12B and …

General Fusion, UKAEA Announce Magnetized Target Fusion Milestone

General Fusion, UKAEA Announce Magnetized Target Fusion Milestone

General Fusion Group Ltd. (NASDAQ: GFUZ) announced a breakthrough with its Lawson Machine 26, reaching electron temperatures over 12 million °C (1.1 keV) using Magnetized Target Fusion (MTF). This milestone signifies a key technological step toward economical and practical fusion energy, achieved with a unique low-speed compression method. The comp…

L3Harris: Tactical Long Into the Global Rearmament Cycle

L3Harris: Tactical Long Into the Global Rearmament Cycle

L3Harris (LHX) offers a pragmatic entry into the global rearmament cycle. The company combines predictable FCF, a $42B backlog, attractive dividend yield, and international expansion with a valuation that looks reasonable versus its cash flow profile. We upgrade to a buy and recommend a mid-term swing trade with clear entry, stop and target levels.

Almonty: Market Is Pricing a Tungsten Crash That Hasn't Arrived

Almonty: Market Is Pricing a Tungsten Crash That Hasn't Arrived

Almonty looks priced for a severe commodity collapse. We think that’s too pessimistic. Operational advances at Sangdong, a shallow global supply base, and steady industrial demand create a setup where upside from a modest recovery in tungsten prices materially outpaces downside. This trade targets that asymmetry with defined entry, stop and targets…

VenHub to Expand Smart Store Deployments Into Multifamily Residential Market; First VenHub Autonomous Retail Store Will Be at Penn Lofts in Bend, Oregon

VenHub to Expand Smart Store Deployments Into Multifamily Residential Market; First VenHub Autonomous Retail Store Will Be at Penn Lofts in Bend, Oregon

VenHub Global, Inc. announces its first deployment of the Smart Store autonomous retail platform in a multifamily residential community, Penn Lofts in Bend, Oregon. This marks a strategic expansion into the multifamily housing sector, offering residents convenient on-site shopping and providing property owners with a valuable amenity to enhance res…

Clearmind Announces Patent Publication in Japan  Covering Treatment for Neurological Movement Disorder

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Clearmind Medicine Inc. announced the publication of a patent application in Japan covering its innovative 3-MMC-based treatment for dyskinesia, including combinations with the neuroprotective compound Palmitoylethanolamide (PEA). This development strengthens Clearmind’s global intellectual property position as it advances therapies for neurologica…

Trekor Announces 41 Million Pounds of Copper Production from Gibraltar and Florence Copper in the Third Quarter

Trekor Announces 41 Million Pounds of Copper Production from Gibraltar and Florence Copper in the Third Quarter

Trekor Metals Limited announced its third-quarter production results, delivering 41 million pounds of copper from its Gibraltar mine and Florence Copper facility. The Gibraltar mine saw a 12% production increase due to higher ore grades and improved processing, while Florence Copper continues ramping up with a 36% production growth over the prior p…

Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests

Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests

Cerenome, Inc. announced a new in-network contract with Florida Blue for their CNSide cerebrospinal fluid tumor diagnostics, adding approximately 6 million covered lives and expanding reimbursement to include CNSide's new molecular profiling tests alongside tumor cell enumeration. This marks a key milestone in expanding CNSide's commercial footprin…

Top KingWin Ltd Announces Name Change to Nexpu Ltd.

Top KingWin Ltd Announces Name Change to Nexpu Ltd.

Top KingWin Ltd has changed its corporate name to Nexpu Ltd. effective August 31, 2026, with Nasdaq recognizing the name change on October 9, 2026. The company will continue trading under the ticker symbol DPU and remains focused on selling data collection and analysis devices, as well as robots.

Helus Pharma to Host Investor Presentation on October 21, 2026

Helus Pharma to Host Investor Presentation on October 21, 2026

Helus Pharma Inc., a clinical-stage biotech company focused on developing novel serotonergic agonists for mental health conditions, announced an investor presentation to discuss its lead drug candidates HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder. The event will feature expert perspectives …

Swvl Announces H1 2026 Results; Revenue Up 59% to $16.2 Million; GCC Revenue Up 107%; Dollar-Pegged Revenue Up to 44% of Revenue; Net Dollar Retention of 123%

Swvl Announces H1 2026 Results; Revenue Up 59% to $16.2 Million; GCC Revenue Up 107%; Dollar-Pegged Revenue Up to 44% of Revenue; Net Dollar Retention of 123%

Swvl Holdings Corp reported robust financial results for the first half of 2026, with revenue increasing by 59% year-over-year to $16.2 million, driven primarily by a 107% revenue surge in the Gulf Cooperation Council (GCC) region and continued growth in Egypt. The company's revenue base improved with 88% recurring revenue and 44% dollar-pegged rev…

Alamar: Buy the Dip — Consumables Revenue Should Drive the Next Leg

Alamar: Buy the Dip — Consumables Revenue Should Drive the Next Leg

Alamar Biosciences is trading off a quick pullback after a recent run. The company’s instrument placements and accelerating consumables sales — highlighted by record Q1 revenue of $26.0M and major academic partnerships — argue for a durable revenue mix shift toward recurring, higher-margin assay sales. This trade idea buys the dip with a defined st…